CL2017003025A1 - Derivados(1,2-b)(1,2,4)de imidazotriazina como agentes antiparasitarios. - Google Patents

Derivados(1,2-b)(1,2,4)de imidazotriazina como agentes antiparasitarios.

Info

Publication number
CL2017003025A1
CL2017003025A1 CL2017003025A CL2017003025A CL2017003025A1 CL 2017003025 A1 CL2017003025 A1 CL 2017003025A1 CL 2017003025 A CL2017003025 A CL 2017003025A CL 2017003025 A CL2017003025 A CL 2017003025A CL 2017003025 A1 CL2017003025 A1 CL 2017003025A1
Authority
CL
Chile
Prior art keywords
imidazotriazine
derivatives
antiparasitic agents
leishmaniasis
compound
Prior art date
Application number
CL2017003025A
Other languages
English (en)
Inventor
Timothy James Miles
Michael George Thomas
Stephen Brand
Elisabet Viayna Gaza
Ian Gilbert
Eun Jung Ko
Martin María Marco
Lars Henrik Sandberg
Original Assignee
Glaxosmithkline Ip Dev Ltd
The Univ Of Dundee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd, The Univ Of Dundee filed Critical Glaxosmithkline Ip Dev Ltd
Publication of CL2017003025A1 publication Critical patent/CL2017003025A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>UN COMPUESTO DE FORMULA (I), O UNA DE SUS SALES, COMPOSICIONES QUE COMPRENDEN EL COMPUESTO, PROCEDIMIENTOS PARA SU PREPARACIÓN Y SU USO EN TERAPIA, POR EJEMPLO, EN EL TRATAMIENTO DE ENFERMEDADES PARASITARIAS TALES COMO ENFERMEDAD DE CHAGAS, TRIPANOSOMIASIS AFRICANA HUMANA (HAT) Y LEISHMANIASIS, PARTICULARMENTE LEISHMANIASIS VISCERAL (VL).</p>
CL2017003025A 2015-05-29 2017-11-28 Derivados(1,2-b)(1,2,4)de imidazotriazina como agentes antiparasitarios. CL2017003025A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15382283 2015-05-29

Publications (1)

Publication Number Publication Date
CL2017003025A1 true CL2017003025A1 (es) 2018-03-16

Family

ID=53398015

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017003025A CL2017003025A1 (es) 2015-05-29 2017-11-28 Derivados(1,2-b)(1,2,4)de imidazotriazina como agentes antiparasitarios.

Country Status (14)

Country Link
US (1) US10065965B2 (es)
EP (1) EP3303336A1 (es)
JP (1) JP2018516265A (es)
CN (1) CN107922419A (es)
AR (1) AR104749A1 (es)
AU (1) AU2016269626B2 (es)
BR (1) BR112017025668A2 (es)
CA (1) CA2987329A1 (es)
CL (1) CL2017003025A1 (es)
CO (1) CO2017011969A2 (es)
CR (1) CR20170546A (es)
TW (1) TW201713661A (es)
UY (1) UY36688A (es)
WO (1) WO2016193111A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017127627A1 (en) 2016-01-21 2017-07-27 The University Of North Carolina At Chapel Hill Compounds for treatment of trypanosomes and neurological pathogens and uses thereof
JOP20190278A1 (ar) * 2017-05-31 2019-11-28 Novartis Ag مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية
EA039324B1 (ru) * 2017-11-06 2022-01-13 Новартис Аг 5,6–конденсированные бициклические соединения и композиции для лечения паразитарных заболеваний
CN108129409B (zh) * 2018-01-22 2020-07-03 三金集团湖南三金制药有限责任公司 一种改进的合成拉莫三嗪的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110077250A1 (en) * 2009-06-26 2011-03-31 Ryder Sean Compounds for modulating rna binding proteins and uses therefor
US9233961B2 (en) 2013-03-15 2016-01-12 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9296754B2 (en) * 2013-03-15 2016-03-29 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
UY35400A (es) 2013-03-15 2014-10-31 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
MY175865A (en) 2013-12-19 2020-07-14 Novartis Ag [1,2,4]triazolo[1,5-a]pyrimidine derivatives as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis

Also Published As

Publication number Publication date
AR104749A1 (es) 2017-08-09
AU2016269626B2 (en) 2019-05-30
BR112017025668A2 (pt) 2018-08-07
CA2987329A1 (en) 2016-12-08
TW201713661A (zh) 2017-04-16
UY36688A (es) 2016-12-30
EP3303336A1 (en) 2018-04-11
US10065965B2 (en) 2018-09-04
AU2016269626A1 (en) 2017-12-14
WO2016193111A1 (en) 2016-12-08
JP2018516265A (ja) 2018-06-21
CN107922419A (zh) 2018-04-17
CR20170546A (es) 2018-04-02
CO2017011969A2 (es) 2018-02-09
US20180141949A1 (en) 2018-05-24

Similar Documents

Publication Publication Date Title
MX379530B (es) Compuestos agonistas del receptor muscarínico m4.
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
UY36112A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
CO2018003969A2 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona
CR20160518A (es) Compuestos para tratar atrofia muscular espinal
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
UY36465A (es) Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico
MX2019012847A (es) Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
UY38625A (es) Compuestos y su uso en el tratamiento del cáncer
MX2016015248A (es) Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal.
CU20170162A7 (es) Derivados de fenil-tieno(2,3-d)pirimidina-hidroxiácido útiles en el tratamiento del cáncer y enfermedades autoinmunes, método de preparación de los mismos y composiciones farmacéuticas que los contienen
CO2018004933A2 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
CL2015002635A1 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
MX2018005725A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer.
MX2018004295A (es) Compuestos, composiciones farmáceuticas y métodos de uso de agonistas de ppar.
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
UY36145A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
CL2015003196A1 (es) Derivados de pirrolo[2,3-d]pirimidina como agonistas del receptor cb2.
CY1120602T1 (el) [1,2,4]τριαζολο[4,3-β]πυριδαζινες για χρηση στη θεραπευτικη αντιμετωπιση πολλαπλασιαστικων ασθενειων
CL2017001539A1 (es) Compuestos indenil, composiciones farmacéuticas y sus usos médicos de los mismos
CR20160529A (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
CL2016001421A1 (es) Derivados de [1,2,4] triazolo [1,5-a] pirimidina como inhibidores de proteasoma para el tratamiento de enfermedades parasitarias como la leishmaniasis.
CY1124151T1 (el) Ενωσεις